Skip to content

Study on the Equivalence of Linaclotide +2L-PEG Regimen and Divided dose 3L-PEG Regimen in Bowel Preparation before Colonoscopy

Study on the Equivalence of Linaclotide +2L-PEG Regimen and Divided dose 3L-PEG Regimen in Bowel Preparation before Colonoscopy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057368
Enrollment
Unknown
Registered
2022-03-09
Start date
2022-03-01
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intestinal diseases

Interventions

test group:Linaclotide 290ug×1 tablet+compound polyethylene glycol electrolyte powder 68.56g×1 bag (1L) orally (21: 00 the night before colonoscopy)+linaclotide 290ug×1 tablet+compound polyethylene gl
control group:Compound polyethylene glycol electrolyte powder 68.56g×2 bags (2L) orally (21: 00 the night before colonoscopy)+compound polyethylene glycol electrolyte powder 68.56g×1 bags (1L) orally

Sponsors

Department of Gastroenterology, the First Affiliated Hospital of Shantou University Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.sign the informed consent form voluntarily; 2.Age 18 ~ 70 years old, male or female.

Exclusion criteria

Exclusion criteria: 1. Have a history of acute myocardial infarction or cerebrovascular accident (within 6 months), and have severe heart, lung, liver, kidney dysfunction and other basic diseases; 2. Those who are taking aspirin, warfarin and other anticoagulant drugs or have coagulation dysfunction; 3. Severe gastroparesis and intestinal obstruction after gastrointestinal resection; 4. Past or current severe constipation (it can be relieved by repeated use of laxatives/enema or physical intervention), and foreign body removal or decompression by colonoscopy; 5. Known or suspected gastrointestinal obstruction or perforation; 6. Pregnant or lactating women; 7. Persons with mental illness who cannot cooperate with the examination; 8. People who are allergic to intestinal preparations; 9. Patients judged by the investigator to be unsuitable for this trial.

Design outcomes

Primary

MeasureTime frame
Boston bowel preparation score;

Secondary

MeasureTime frame
Patient tolerance score;Patient compliance;Total defecation time (the night before colonoscopy);Number of defecation (the night before colonoscopy);Detection rate of intestinal polyps;Detection rate of intestinal adenoma;Cecal intubation rate;Incidence of adverse reactions;

Countries

China

Contacts

Public ContactCai Xianbin

The First Affiliated Hospital of Shantou University Medical College

cxbin1@qq.com+86 13592801216

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026